HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death

Leukemia

Volumn 17, Issue 11, 2003, Pages 2074-2080

  Lickliter, J D ^a,b,c,d   Wood, N J ^b,c   Johnson, L ^b   McHugh, G ^b   Tan, J ^c   Wood, F ^b   Cox, J ^a   Wickham, N W ^b,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

^c JAMES COOK UNIVERSITY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Apoptosis; Bcl 2; Cytarabine; HA14 1; Lymphoma

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; CARBOXYLIC ACID DERIVATIVE; CYTARABINE; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BLAST CELL; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL DEATH; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA CELL; LYMPHOMA CELL; PRIORITY JOURNAL;

EID: 0242475256     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403102     Document Type: Article

References (31)

1. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 1999; 59 (Suppl): 1685s-1692s.
2. Eischen CM, Woo D, Roussel MF, Cleveland TL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol 2001; 21: 5063-5070.
3. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11: 68-75.
4. Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene 1995; 11: 1389-1394.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
6. Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Oncol 2001; 13: 453-462.
7. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.
8. Puthalakath H, Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-512.
9. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
10. Huang Z. The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. Chem Biol 2002; 9: 1059-1072.
11. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
12. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood 1997; 89: 243-255.
13. Campos L, Sabido O, Viallet A, Vasselon C, Guyotat D. Expression of apoptosis-controlling proteins in acute leukemia cells. Leuk Lymphoma 1999; 33: 499-509.
14. Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30: 803-808.
15. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-3055.
16. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4: 232-234.
17. Yuen AR, Sikic BI. Clinical studies of antisense therapy in cancer. Front Biosci 2000; 5: D588-D593.
18. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-1823.
19. Morris MJ, Tong WP, Cordon-Cardo C, Drobnjak M, Kelly WK, Slovin SF et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679-683.
20. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000; 97: 7124-7129.
21. Yamaguchi H, Paranawithana SR. Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 2002; 62: 466-471.
22. Milella M, Estrov Z, Kornblau SM, Carter BZ, Konopleva M, Tari A et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002; 99: 3461-3464.
23. Fennell DA, Cotter FE. Controlling the mitochondrial gatekeeper for effective chemotherapy. Br J Haematol 2000; 111: 52-60.
24. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795-808.
25. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. Blood 2002; 100: 1765-1773.
26. Meilhac O, Escargueil-Blanc I, Thiers JC, Salvayre R, Negre-Salvayre A. Bcl-2 alters the balance between apoptosis and necrosis, but does not prevent cell death induced by oxidized low density lipoproteins. FASEB J 1999; 13: 485-494.
27. Halestrap AP, Kerr PM, Javadov S, Woodfield KY. Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim Biophys Acta 1998; 1366: 79-94.
28. Chen J, Freeman A, Liu J, Dai Q, Lee RM. The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195. Mol Cancer Ther 2002; 1: 961-967.
29. Takenaka K, Nagafuji K, Harada M, Mizuno S, Miyamoto T, Makino S et al. In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95). Blood 1996; 88: 2871-2877.
30. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001; 3: 183-191.
31. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001; 44: 4313-4324.